CHADDS FORD, Pa., Feb. 3, 2012 /PRNewswire/ -- Endo Pharmaceuticals Holdings (Nasdaq: ENDP) will announce its fourth quarter and full year 2011 financial results on February 24, 2012 and will host a conference call and webcast at 8:30 a.m. ET that day to discuss these results.
David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, and Blaine Davis, vice president, corporate affairs will host the call.
Investors and other interested parties may call 800-561-2718 (domestic) or 617-614-3525 (international) and enter passcode 29896529. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from February 24 at 10:30 a.m. ET until 12:00 p.m. ET on March 9 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 35294180.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 p.m. ET on March 9. The replay can be accessed by clicking on “Events” in the Investor Relations section of the website.
About Endo
Endo Pharmaceuticals Holdings is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments - branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals Holdings and its businesses American Medical Systems, HealthTronics and Qualitest Pharmaceuticals, please visit http://www.endo.com/.
SOURCE Endo Pharmaceuticals Holdings
